

Instance: composition-en-70fa014e07592e69938a0c03f0ec3015
InstanceOf: CompositionUvEpi
Title: "Composition for vidprevtyn Package Leaflet"
Description:  "Composition for vidprevtyn Package Leaflet"
Usage: #inline

* identifier.system = ""

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mock)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - vidprevtyn"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet 
1. What VidPrevtyn Beta is and what it is used for<br />
2. What you need to know before you receive  VidPrevtyn Beta 
3. How VidPrevtyn Beta is given 
4. Possible side effects<br />
5. How to store VidPrevtyn Beta 
6. Contents of the pack and other information </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What vidprevtyn is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What vidprevtyn is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>VidPrevtyn Beta is a vaccine used for preventing COVID-19. VidPrevtyn Beta is given to adults who previously received either mRNA or adenoviral vector 
COVID-19 vaccine. </p>
<p>The vaccine stimulates the immune system (the body s natural defences) to produce specific 
antibodies that work against the virus, giving protection against COVID-19. None of the ingredients 
in this vaccine can cause COVID-19. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take vidprevtyn"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take vidprevtyn"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not use VidPrevtyn Beta:<br />
If you are allergic to the active substance or any of the other ingredients of this medicine (listed in 
section 6);<br />
If you are allergic to octylphenol ethoxylate, a substance that is used in the manufacturing process. 
Small amounts of this substance may remain after manufacturing.  </p>
<p>Warnings and precautions<br />
Talk to your doctor, pharmacist or nurse before you are given the vaccine if:<br />
<em> you have ever had a severe allergic reaction after any other vaccine injection or after you were 
given VidPrevtyn Beta in the past;<br />
</em> you have ever fainted following any needle injection; 
* you have a severe illness or infection with a high temperature (over 38  C). However, you can 
have your vaccination if you have a mild fever or upper airway infection like a cold.<br />
* you have a bleeding problem, you bruise easily or you use a medicine to prevent blood clots. 
* you have a weakened immune system (immunodeficiency) or you are using medicines that 
weaken the immune system (such as high-dose corticosteroids or cancer medicines).  </p>
<p>As with any vaccine, VidPrevtyn Beta may not fully protect all those who receive it. It is not known 
how long you will be protected. </p>
<p>Children and adolescents 
VidPrevtyn Beta is not recommended for children aged under 18 years. Currently there is no 
information available on the use of VidPrevtyn Beta in children and adolescents younger than years of age. </p>
<p>Other medicines and VidPrevtyn Beta 
Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other 
medicines or vaccines. </p>
<p>Pregnancy and breast-feeding<br />
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor, pharmacist or nurse for advice before you receive this vaccine. </p>
<p>Driving and using machines<br />
Some of the side effects of VidPrevtyn Beta mentioned in section 4 (Possible side effects) may 
temporarily affect your ability to drive or use machines. Wait until these effects have worn off before 
you drive or use machines. </p>
<p>VidPrevtyn Beta contains sodium and potassium<br />
This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially  sodium-
free .<br />
This medicine contains less than 1 mmol potassium (39 mg) per dose, that is to say essentially 
 potassium-free .  </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take vidprevtyn"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take vidprevtyn"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Your doctor, pharmacist or nurse will inject the vaccine into a muscle, usually in your upper arm. </p>
<p>You will receive one injection. 
It is recommended that you receive VidPrevtyn Beta once as a booster dose at minimum 4 months 
following the prior vaccination series with either mRNA or adenoviral vector COVID-19 vaccine. </p>
<p>After the injection, your doctor, pharmacist or nurse will watch over you for around 15 minutes to 
monitor for signs of an allergic reaction. </p>
<p>If you have any further questions on the use of this vaccine, ask your doctor, pharmacist or nurse. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Most of the side effects occur within 3 days of getting the vaccine and go away within a few days of 
appearing. If symptoms persist, contact your doctor, pharmacist or nurse.  </p>
<p>Get urgent medical attention if you get symptoms of a severe allergic reaction shortly after 
vaccination. Such symptoms may include:  </p>
<ul>
<li>feeling faint or light-headed  </li>
<li>changes in your heartbeat  </li>
<li>shortness of breath  </li>
<li>wheezing </li>
<li>swelling of your lips, face, or throat  </li>
<li>itchy swelling under the skin (hives) or rash  </li>
<li>feeling sick (nausea) or vomiting  </li>
<li>stomach pain. </li>
</ul>
<p>The following side effects may occur with VidPrevtyn Beta: 
Side effects which may affect up to 1 in 100 people may not have all been detected in the clinical 
studies done to date. </p>
<p>Very common (may affect more than 1 in 10 people):<br />
* Headache 
* Muscle pain 
* Joint pain 
* Feeling unwell 
* Chills 
* Pain where the vaccine is injected </p>
<p>Common (may affect up to 1 in 10 people):<br />
<em> Fever (  38.0 C) 
* Tiredness<br />
</em> Feeling sick (nausea) 
* Diarrhoea 
* Redness or swelling where the vaccine is injected </p>
<p>Uncommon (may affect up to 1 in 100 people): 
* Enlarged lymph nodes 
* Itching, bruising or warmth where the vaccine is injected. </p>
<p>Rare (may affect up to 1 in 1,000 people) 
* Dizziness </p>
<p>Not known (cannot be estimated from available data): 
* Allergic reactions such as rash or hives or swelling of the face 
* Severe allergic reactions (anaphylaxis) </p>
<p>Reporting of side effects<br />
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side 
effects not listed in this leaflet. You can also report side effects directly via the national reporting 
system listed in Appendix V. By reporting side effects you can help provide more information on the 
safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store vidprevtyn"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store vidprevtyn"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this vaccine out of the sight and reach of children. </p>
<p>Information about storage, use and handling are described in the section intended for healthcare 
professionals at the end of the package leaflet. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What VidPrevtyn Beta contains<br />
<em> There are two multidose vials (antigen vial and adjuvant vial) that must be mixed before use. 
After mixing, the vaccine vial contains 10 doses of 0.5 mL. 
* One dose (0.5 mL) contains 5 micrograms of recombinant SARS-CoV-2 spike protein antigen 
(B.1.351 strain).<br />
</em> AS03 is included in this vaccine as an adjuvant to enhance production of specific antibodies. 
This adjuvant contains squalene (10.69 milligrams), DL- -tocopherol (11.86 milligrams) and 
polysorbate 80 (4.86 milligrams). 
* The other ingredients are: sodium dihydrogen phosphate monohydrate, disodium phosphate 
dodecahydrate, sodium chloride, polysorbate 20, disodium hydrogen phosphate, potassium 
dihydrogen phosphate, potassium chloride, water for injections.  </p>
<p>What VidPrevtyn Beta looks like and contents of the pack 
* The antigen solution is a colourless, clear liquid.<br />
* The adjuvant emulsion is a whitish to yellowish homogeneous milky liquid. 
* Prior to administration, the two components should be mixed. The mixed vaccine is a whitish 
to yellowish homogeneous milky liquid emulsion. </p>
<p>Each pack contains 10 multidose antigen vials and 10 multidose adjuvant vials. 
* Each antigen vial contains 2.5 mL antigen solution in a multidose vial (type 1 glass) with a 
stopper (chlorobutyl) and an aluminium seal with a green plastic flip-off cap<br />
* Each adjuvant vial contains 2.5 mL adjuvant emulsion in a multidose vial (type 1 glass) with a 
stopper (chlorobutyl) and an aluminium seal with a yellow plastic flip-off cap. </p>
<p>After mixing the antigen solution with the adjuvant emulsion, the vial contains 10 doses of 0.5 mL. </p>
<p>Marketing Authorisation Holder<br />
Sanofi Pasteur - 14 Espace Henry Vall e - 69007 Lyon   France </p>
<p>Manufacturer 
Sanofi Pasteur - 1541 avenue Marcel M rieux - 69280 Marcy l'Etoile   France </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi / Belgique /Belgien 
Sanofi Belgium 
tel.: +32 2 710.54.Lietuva 
Swixx Biopharma UAB 
Tel.: +370 5 236 91 <br />
Swixx Biopharma EOOD<br />
Te .: +359 (0)2 4942 Luxembourg/Luxemburg 
Sanofi Belgium 
tel.: +32 2 710.54. esk  republika 
Sanofi s.r.o. 
Tel: +420 233 086 Magyarorsz g 
sanofi-aventis zrt 
Tel.: +36 1 505 0Danmark 
Sanofi A/S 
Tel: +45 4516 7Malta 
Sanofi S.r.l. 
Tel: +39 02 39394 Deutschland 
Sanofi-Aventis Deutschland GmbH 
Tel.: 0800 54 54 Tel. aus dem Ausland: +49 69 305 21 Nederland 
Sanofi B.V. 
Tel: +31 20 245 4Eesti 
Swixx Biopharma O<br />
Tel.: +372 640 10 Norge 
Sanofi-aventis Norge AS 
Tel: + 47 67 10 71 <br />
   . .<br />
 : +30.210.8009 sterreich 
sanofi-aventis GmbH 
Tel: +43 1 80 185-0. Espa a 
sanofi-aventis, S.A.<br />
Tel: +34 93 485 94 Polska 
Sanofi Pasteur Sp. z o.o. 
Tel.: + 48 22 280 00 France 
Sanofi Pasteur Europe 
T l: 0800 222 Appel depuis l tranger : +33 1 57 63 23 Portugal 
Sanofi   Produtos Farmac uticos, Lda. 
Tel: + 351 21 35 89 Hrvatska 
Swixx Biopharma d.o.o 
Tel.: +385 1 2078 Ireland 
sanofi-aventis Ireland T/A SANOFI 
Tel: + 353 (0) 1 4035 Rom nia 
Sanofi Romania SRL 
Tel.: +40(21) 317 31 Slovenija 
Swixx Biopharma d.o.o. 
Tel.: +386 1 235 51  sland 
Vistor 
Tel : +354 535 7Slovensk  republika 
Swixx Biopharma s.r.o. 
Tel.: +421 2 208 33 Italia 
Sanofi S.r.l. 
Tel: 800536Suomi/Finland 
Sanofi Oy 
Tel: +358 (0) 201 200 <br />
C.A. Papaellinas Ltd. 
 .: +357 22 741Sverige 
Sanofi AB 
Tel: +46 8-634 50 Latvija 
Swixx Biopharma SIA 
Tel.: +371 6 616 4United Kingdom (Northern Ireland) 
sanofi-aventis Ireland Ltd. T/A SANOFI 
Tel: +44 (0) 800 035 2This leaflet was last revised in  </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      

